home / stock / zlab / zlab news


ZLAB News and Press, Zai Lab Limited From 01/06/22

Stock Information

Company Name: Zai Lab Limited
Stock Symbol: ZLAB
Market: NASDAQ
Website: zailaboratory.com

Menu

ZLAB ZLAB Quote ZLAB Short ZLAB News ZLAB Articles ZLAB Message Board
Get ZLAB Alerts

News, Short Squeeze, Breakout and More Instantly...

ZLAB - Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) ha...

ZLAB - Zai Lab Announces Upcoming Presentations at January Investor Conferences

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following vir...

ZLAB - Tracking Ron Baron's BAMCO Portfolio - Q3 2021 Update

BAMCO’s 13F portfolio value increased from $43.68B to $44.15B this quarter. Ron Baron increased Zillow Group, Hyatt Hotels, Taiwan Semi, and Spotify while decreasing Manchester United, Zai Lab, and GDS Holdings. Their top five positions are at ~25% of the overall portfolio....

ZLAB - Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the promotion of Harald Reinhart, M.D., from his current role as ...

ZLAB - Week In Review: BeiGene Completes $3.5 Billion IPO On Shanghai STAR Board

BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai. Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Ar...

ZLAB - Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART(TM) (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

VYVGART is the first and only FDA-approved neonatal Fc receptor blocker 68% of anti-acetylcholine receptor (AChR) antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis - Activities of Daily Living (MG-ADL) scale compar...

ZLAB - Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2021 Update

Halvorsen's 13F portfolio value increased from $32.98B to $36.04B this quarter. The number of positions increased from 88 to 96. Viking Global added McDonald’s and increased General Electric, Humana, Brookfield Asset Management, and Parker Hannifin while dropping Aon plc during...

ZLAB - BKKT, IRNT and PCSA among mid-day movers

Gainers: Adagio (NASDAQ:ADGI) +101%. Kaixin (NASDAQ:KXIN) +34%. Calliditas (NASDAQ:CALT) +25%. Euro Tech Holdings (NASDAQ:CLWT) +19%. Mechel (NYSE:MTL) +17%. Processa (NASDAQ:PCSA) +17%. Versus Systems (NASDAQ:VS) +17%. Assertio (NASDAQ:ASRT) +17%. Zai Lab (NASDAQ:ZLAB) +17%. Petros Pharmaceu...

ZLAB - Paratek, Zai Labs up on Chinese approval of Nuzyra for pneumonia, skin infections

Paratek Pharmaceuticals (PRTK +12.2%) is up 12% after announcing that China's National Medical Products Administration approved Nuzyra (omadacycline) for community-acquired bacterial pneumonia and bacterial skin infections. Nuzyra was licensed to Zai Labs (ZLAB +15.7%) in ...

ZLAB - China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections 

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA ...

Previous 10 Next 10